Skip to main content

Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says

The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.